The markets couldn’t find a direction in the early morning trade, and U.S. equity futures were relatively flat ahead of the open. President Trump touched down in Israel today, and traders will be focused on the public statements that Trump will be making, as they could move the markets. For now, it’s a wait and see game with Trump. However, there are some stocks moving ahead of the bell, and traders may be looking at these small-cap stocks to trade.
Radius Health Inc (NASDAQ: RDUS) shares are up over 10% ahead of the bell, after Amgen and UCB provided Phase III results, and the data indicated that there could be an increased chance of serious heart problems in patients taking its osteoporosis treatment. That in mind, this boosted Radius Health, as RDUS was granted FDA approval in late April 2017 for its osteoporosis drug TYMLOS.
Check out RDUS on the daily chart:
If you notice the chart above, RDUS formed a falling wedge, and indicated it could have potentially reversed, at the time. After the positive catalyst, RDUS is trading above the $40 level, and is set to break out of its previous downtrend at the open.
La Jolla Pharmaceutical Company (NASDAQ: LJPC) is down over 10% during the pre-market session, after mixed results of its ATHOS-3 Phase III study of LJPC-501 was published over the weekend. Although La Jolla Pharmaceutical met its primary endpoint, LJPC-501 was unable to improve total organ function, nor was it able to reduce mortality.
Take a look at LJPC on the daily chart:
Cheetah Mobile Inc. (NYSE: CMCM) shares are up just over 10% ahead of the bell, after it announced its first quarter 2017 unaudited consolidated financial results. Cheetah Mobile grew its total revenues by 6.8% year over year and net income attributable to CMCM shareholders by over 750% year over year. Additionally, the company’s non-GAAP net income attributable to CMCM shareholders grew by 13.2% year over year.
Here’s a look at CMCM on the daily chart:
Nutraceutical International Corporation (NASDAQ: NUTR) is up over 45%, after the company entered into a definitive agreement to be acquired by HGGC LLC, a private equity firm, for approximately $446M, including debt. That in mind, NUTR shareholders would receive $41.80 in cash, excluding interest, for each outstanding share they own.
Nutraceutical Chairman and CEO Bill Gay stated, “We are excited to be joining forces with HGGC, which is a world-class private equity firm. HGGC’s expertise in formulating strategic growth plans for middle-market companies will be a great platform for the future of Nutraceutical. We expect that the combination of HGGC’s strategic insights and the deep industry experience and knowledge of our management team will help us continue to build and grow.”
Check out NUTR on the daily chart:
Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares are up just over 20% ahead of the bell, after the company announced that it received its first development milestone payment from Valeant Pharmaceuticals.
EyeGate Pharmaceuticals President and Chief Executive Officer Stephen From stated, “We have made significant progress in the development of EGP-437 for the treatment of post-operative ocular inflammation and pain in ocular surgery patients since initiating our first study in this large indication last year, evidenced by this first milestone payment under the Valeant partnership in ocular surgery.”
Take a look at EYEG on the daily chart, as of Friday’s close: